A Phase 1 interventional study of Blinatumomab (MT103) in Non-Hodgkin's Lymphoma, Relapsed, sponsored by Amgen Research (Munich) GmbH. Completed at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.
Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lymphoma, Non-Hodgkin by Amgen — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Amgen.
Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 7 in phase 1, and was the 9th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 20 studies in Lymphoma, Non-Hodgkin by Amgen is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 39 across the 15 interventional studies, 1,837 across the 1 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Amgen Research (Munich) GmbH, one of the names counted as Amgen. Under that name alone:
Amgen Research (Munich) GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a continuous infusion of Blinatumomab (MT103) is safe in the treatment of relapsed Non-Hodgkin's Lymphoma.
Furthermore, the study is intended to provide pharmacokinetic and pharmacodynamic data of Blinatumomab as well as to get first indication of tumour activity.
Non-Hodgkin's Lymphoma (NHL) represents the 6th most common cancer. Globally, around 165,000 new cases are diagnosed each year, with approximately 90,000 deaths per year. The vast majority of NHLs are B-cell derived (90%) and express common B-cell antigens such as CD19, CD20 and CD22. NHL can be divided into indolent (low-grade) and aggressive (high-grade) lymphomas. Still almost all patients with advanced stage indolent disease will die from their disease. Therefore, a high medical need exists to develop novel agents that further improve the survival of NHL patients.
Blinatumomab (MT103) is a bispecific antibody derivative, anti-CD19 x anti-CD3, designed to link B-cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against CD19+ cells. Data of prior phase I studies show evidence of biological activity in humans. In vitro and ex-vivo data suggest that a longterm presence of the drug in target tissues may provide antitumour activity.
The study investigates the safety and tolerability of different doses of Blinatumomab administration in a continuous infusion regimen. Maximum tolerated dose (MTD) will be defined in a classical 3+3 dose escalation regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with first or later relapse of histologically (World Health Organisation classification) confirmed:
Exclusion Criteria:
Abnormal laboratory values as defined below:
Abnormal renal or hepatic function as defined below:
Indication of hypercoagulative state as defined below:
-antithrombin activity \<LLN
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
Biological: Blinatumomab (MT103)
Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
Also known as: Blinatumomab, MT103, AMG103, BLINCYTO™
Number of Participants With Adverse Events
Participants reporting at least one occurence of any adverse event including clinical symptoms, laboratory abnormalities, serious adverse events, and treatment-limiting adverse events
Time frame: From the first infusion of blinatumomab until the safety follow-up visit 2 weeks after end of the treatment period, including the consolidation and relapse periods. The median treatment duration was 33.24 days.
Serum Concentration of Blinatumomab
The steady state serum concentration (Css), summarized as the observed concentrations collected at least 10 hours after the start of continuous intravenous infusion or within the sampling window at the end of infusion. Concentrations below the lower limit of quantitation (100 pg/mL) were excluded from analysis.
Time frame: Up to 24 hours after the end of infusion.
Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)
Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Best clinical response is defined as the best response achieved during the course of the study, with response defined as: Complete Response, Complete Response Unconfirmed, Partial Response, Stable Disease, and Progressive Disease. In this analysis minimal response is set to stable disease as intended in the response categories according to the Cheson criteria. An independent external review by a radiologist (computed tomography scans) and a pathologist (biopsies) was performed to confirm response status. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.
Time frame: Assessed after 4 and 8 weeks of treatment
Objective Tumor Response According to the Cheson Criteria (With Minimal Response)
Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Minimal response was treated as a separate response category in this analysis. Best clinical response was defined as the best response achieved during the course of the study, whereby the following order was applied: Complete Response, Complete Response Unconfirmed, Partial Response, Minimal Response, Stable Disease, and Progressive Disease. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.
Time frame: Assessed after 4 and 8 weeks of treatment
Participants were enrolled from 22 June 2004 through 18 July 2011
| Milestone | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d |
|---|---|---|---|---|---|---|
| Started | 12 | 13 | 6 | 9 | 32 | 4 |
| Completed | 12 | 5 | 4 | 4 | 16 | 1 |
| Not completed | 0 | 8 | 2 | 5 | 16 | 3 |
| Withdrew: Adverse event | 0 | 4 | 1 | 4 | 12 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: End of study | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 3 | 0 | 0 | 2 | 0 |
Participants reporting at least one occurence of any adverse event including clinical symptoms, laboratory abnormalities, serious adverse events, and treatment-limiting adverse events
| participants | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 12 | 13 | 6 | 9 | 32 | 4 |
The steady state serum concentration (Css), summarized as the observed concentrations collected at least 10 hours after the start of continuous intravenous infusion or within the sampling window at the end of infusion. Concentrations below the lower limit of quantitation (100 pg/mL) were excluded from analysis.
| pg/mL | Blinatumomab 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d | Blinatumomab 90 µg/m²/d |
|---|---|---|---|---|---|
| Serum Concentration of Blinatumomab | 210 ± 84.9 | 651 ± 307 | 1210 ± 476 | 2730 ± 985 | 3490 ± 904 |
Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Best clinical response is defined as the best response achieved during the course of the study, with response defined as: Complete Response, Complete Response Unconfirmed, Partial Response, Stable Disease, and Progressive Disease. In this analysis minimal response is set to stable disease as intended in the response categories according to the Cheson criteria. An independent external review by a radiologist (computed tomography scans) and a pathologist (biopsies) was performed to confirm response status. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.
| participants | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d |
|---|---|---|---|---|---|---|
| Complete response | 0 | 1 | 1 | 3 | 5 | 1 |
| Complete response unconfirmed | 0 | 0 | 0 | 0 | 5 | 0 |
| Partial response | 0 | 2 | 0 | 5 | 6 | 1 |
| Stable disease | 6 | 7 | 2 | 0 | 7 | 1 |
| Progressive disease | 6 | 3 | 2 | 0 | 7 | 0 |
| Not available | 0 | 0 | 1 | 1 | 2 | 1 |
Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Minimal response was treated as a separate response category in this analysis. Best clinical response was defined as the best response achieved during the course of the study, whereby the following order was applied: Complete Response, Complete Response Unconfirmed, Partial Response, Minimal Response, Stable Disease, and Progressive Disease. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.
| participants | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d |
|---|---|---|---|---|---|---|
| Complete response | 0 | 1 | 1 | 3 | 5 | 1 |
| Complete response unconfirmed | 0 | 0 | 0 | 0 | 5 | 0 |
| Partial response | 0 | 2 | 0 | 5 | 6 | 1 |
| Minimal response | 1 | 1 | 1 | 0 | 2 | 1 |
| Stable disease | 5 | 6 | 1 | 0 | 5 | 0 |
| Progressive disease | 6 | 3 | 2 | 0 | 7 | 0 |
| Not available | 0 | 0 | 1 | 1 | 2 | 1 |
Collected over From the first infusion of blinatumomab until the safety follow-up visit 2 weeks after end of the treatment period, including the consolidation and relapse periods. The median treatment duration was 33.24 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinatumomab ≤ 5 µg/m²/d | — | 8/12 (66.7%) | 12/12 (100%) |
| Blinatumomab 15 µg/m²/d | — | 10/13 (76.9%) | 13/13 (100%) |
| Blinatumomab 30 µg/m²/d | — | 6/6 (100%) | 6/6 (100%) |
| Blinatumomab 60 µg/m²/d Flat | — | 9/9 (100%) | 9/9 (100%) |
| Blinatumomab 60 µg/m²/d Step | — | 22/32 (68.8%) | 32/32 (100%) |
| Blinatumomab 90 µg/m²/d | — | 4/4 (100%) | 4/4 (100%) |
| Blinatumomab Overall | — | 59/76 (77.6%) | 76/76 (100%) |
| Event | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d | Blinatumomab Overall |
|---|---|---|---|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 3/12 | 6/13 | 6/6 | 7/9 | 16/32 | 4/4 | 42/76 |
| EncephalopathyNervous system disorders | 0/12 | 0/13 | 0/6 | 2/9 | 2/32 | 2/4 | 6/76 |
| Lipase increasedInvestigations | 0/12 | 0/13 | 0/6 | 0/9 | 0/32 | 1/4 | 1/76 |
| ConvulsionNervous system disorders | 0/12 | 0/13 | 0/6 | 0/9 | 0/32 | 1/4 | 1/76 |
| PyrexiaGeneral disorders | 0/12 | 3/13 | 0/6 | 0/9 | 4/32 | 0/4 | 7/76 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/13 | 1/6 | 0/9 | 1/32 | 0/4 | 2/76 |
| LeukopeniaBlood and lymphatic system disorders | 1/12 | 2/13 | 1/6 | 0/9 | 3/32 | 0/4 | 7/76 |
| Catheter site infectionInfections and infestations | 0/12 | 1/13 | 1/6 | 1/9 | 1/32 | 0/4 | 4/76 |
| PneumoniaInfections and infestations | 0/12 | 1/13 | 1/6 | 0/9 | 0/32 | 0/4 | 2/76 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 0/13 | 1/6 | 0/9 | 0/32 | 0/4 | 1/76 |
| Event | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d | Blinatumomab Overall |
|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/12 | 11/13 | 6/6 | 9/9 | 26/32 | 4/4 | 58/76 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 3/13 | 5/6 | 4/9 | 12/32 | 2/4 | 27/76 |
| C-reactive protein increasedInvestigations | 5/12 | 5/13 | 5/6 | 6/9 | 12/32 | 3/4 | 36/76 |
| Fibrin D dimer increasedInvestigations | 2/12 | 4/13 | 5/6 | 4/9 | 2/32 | 3/4 | 20/76 |
| LymphopeniaBlood and lymphatic system disorders | 6/12 | 3/13 | 2/6 | 7/9 | 12/32 | 1/4 | 31/76 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/12 | 1/13 | 1/6 | 7/9 | 16/32 | 3/4 | 31/76 |
| Protein total decreasedInvestigations | 0/12 | 0/13 | 0/6 | 2/9 | 5/32 | 3/4 | 10/76 |
| Weight decreasedInvestigations | 3/12 | 5/13 | 2/6 | 1/9 | 11/32 | 3/4 | 25/76 |
| Weight increasedInvestigations | 1/12 | 5/13 | 4/6 | 5/9 | 14/32 | 3/4 | 32/76 |
| HeadacheNervous system disorders | 2/12 | 4/13 | 4/6 | 6/9 | 11/32 | 3/4 | 30/76 |
| Age, Continuous(years) | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d | Total |
|---|---|---|---|---|---|---|---|
| Mean | 66.8 ± 7.5 | 64.8 ± 8.0 | 53.3 ± 9.4 | 59.7 ± 11.9 | 57.1 ± 14.9 | 64.8 ± 5.6 | 60.3 ± 12.4 |
| Sex: Female, Male(Participants) | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 4 | 1 | 0 | 11 | 1 | 19 |
| Male | 10 | 9 | 5 | 9 | 21 | 3 | 57 |
| Race (NIH/OMB)(Participants) | Blinatumomab ≤ 5 µg/m²/d | Blinatumomab 15 µg/m²/d | Blinatumomab 30 µg/m²/d | Blinatumomab 60 µg/m²/d Flat | Blinatumomab 60 µg/m²/d Step | Blinatumomab 90 µg/m²/d | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 12 | 13 | 6 | 9 | 32 | 4 | 76 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Jun 2004, a primary completion of Aug 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Amgen Research (Munich) GmbH →